RECOVERY · Spray
BPC Spray.
Oral BPC-157 for gut and systemic healing
How it works
Class & mechanism.
In short
BPC-157 spray delivers the gastric-derived healing peptide through three distinct routes: sublingual (oral — gut lining, leaky gut, IBD), nasal (direct brain access via olfactory nerve for TBI and cognitive support), and topical (open wounds and burns only — intact skin blocks absorption). Each route targets different tissue with different bioavailability. Sublingual is best for GI conditions; nasal is best for brain/CNS targets; injection remains best for musculoskeletal injuries. Note: the RBT BPC-157 nasal spray is no longer manufactured as of early 2026.
Class
Synthetic Peptide — Multi-Route Delivery (Sublingual · Nasal · Topical)
Mechanism
BPC-157 spray delivers the same 15-amino acid sequence as injectable BPC-157, but exploits a unique property that distinguishes it from nearly every other therapeutic peptide: native stability in human gastric juice. While most peptides are rapidly degraded by stomach acid and proteolytic enzymes, BPC-157 was originally isolated from gastric juice — meaning it is natively resistant to GI degradation. The spray format enables three distinct delivery routes, each with a different tissue target and pharmacokinetic profile. Sublingual (oral): sprayed into the mouth and held under the tongue or against the buccal mucosa for 60–90 seconds before swallowing. This achieves direct mucosal contact with the entire oral cavity, oesophagus, and stomach lining — making it the only route where swallowing is a feature, not a bug. Systemic bioavailability via this route is lower than injection (~30–50%) but sufficient for gut-localized repair and modest systemic support. Nasal (intranasal): the only delivery route that provides direct access to the brain without crossing the blood-brain barrier. BPC-157 travels through the perineural spaces surrounding the olfactory and trigeminal nerves — two pathways running from the roof of the nasal cavity straight into the frontal cortex and hippocampus — arriving in brain tissue within 15–30 minutes of application. It also achieves faster systemic absorption than oral routes, with peak blood levels in 5–15 minutes vs. 45–90 minutes orally. Systemic bioavailability is estimated at ~30–50%. Note: as of early 2026, the Retail Biotech Trust (RBT) BPC-157 nasal spray is no longer manufactured; a combination TB-500 + BPC-157 nasal formulation may be available as a replacement. Topical (wound application): BPC-157 has a molecular weight of ~1,419 Daltons — well above the ~500 Dalton threshold for passive skin permeability. Through intact skin, systemic absorption is negligible without a penetration enhancer. Through broken skin — open wounds, cuts, abrasions, burns, post-procedure sites — the barrier is disrupted, allowing local tissue contact and meaningful localized signaling via VEGF upregulation, collagen synthesis, and inflammatory cytokine modulation. Route decision: sublingual → gut healing; nasal → brain/CNS + needle-free systemic; topical → open wounds only; injection → musculoskeletal (tendons, joints) where highest systemic bioavailability is needed.
Personalized Peptides provides DNA-driven peptide recommendations — we are not a compounding pharmacy, peptide synthesis company, or clinical provider.
Did you know
BPC-157 was discovered because scientists were puzzled by the stomach's ability to constantly regenerate its own lining despite bathing in acid strong enough to dissolve metal — they found this peptide living inside that acid, protecting and rebuilding tissue. Decades later, that same acid-resistance makes it one of the only peptides you can take as a spray, a nostril inhale, or directly onto a wound — and it still works.
Benefits
What it does.
Gut mucosal repair — sublingual spray delivers BPC-157 directly to the oral cavity, oesophagus, and stomach lining, targeting ulcers, NSAID-induced damage, and intestinal barrier dysfunction at the site of contact
Brain access without the blood-brain barrier — nasal spray travels via olfactory and trigeminal perineural pathways into the frontal cortex and hippocampus within 15–30 minutes, the only delivery route capable of bypassing the BBB entirely
Needle-free systemic support — nasal spray achieves faster systemic absorption than oral (peak blood levels in 5–15 min) with comparable bioavailability (~30–50%), suitable for users who cannot or prefer not to inject
Leaky gut and IBD management — sublingual route may support tight junction repair and intestinal permeability restoration, potentially addressing the underlying gut barrier dysfunction rather than masking symptoms
Post-concussion and TBI recovery — nasal spray targets brain tissue directly, studied in preclinical models for neurotransmitter modulation (dopamine, serotonin) and neuroinflammation reduction following brain injury
Open wound and burn healing — topical spray applied to broken skin promotes local tissue repair, angiogenesis, and re-epithelialisation in wounds, burns, abrasions, and post-procedure sites where the skin barrier is already disrupted
Gut-brain axis modulation — sublingual BPC-157 may produce secondary neurological benefits through the enteric-CNS connection, a pathway injectable routes are less likely to specifically engage
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
What this does not mean
BPC-157 (spray — all routes) is a research chemical. The information on this page is educational and does not constitute medical advice, diagnosis, or treatment. BPC-157 is not FDA-approved for treating ulcers, gastrointestinal conditions, traumatic brain injury, wound healing, or any other use. This page does not recommend, endorse, or prescribe any compound for human use. Some product formulations referenced (including the RBT BPC-157 nasal spray) may no longer be available — verify current product availability. Always consult a qualified healthcare provider before making health decisions. Personalized Peptides provides DNA-driven educational context and test interpretation — not clinical protocols or pharmaceutical recommendations.
BPC-157 is uniquely stable in human gastric juice — it was originally isolated from it — making it one of the only therapeutic peptides that retains biological activity after oral ingestion. This gastric stability is the property that makes oral/sublingual spray viable, confirmed across multiple publications by Sikiric et al. and validated in early-phase IBD clinical trials.
SOURCE · PMC7096228 — Stable Gastric Pentadecapeptide BPC 157; Sikiric P et al., multiple publications
Oral and intragastric administration of BPC-157 demonstrates protective effects against alcohol-induced gastric mucosal damage, NSAID-induced ulceration, and inflammatory bowel conditions — with equipotent dosing to injectable routes for GI-specific indications in preclinical models.
SOURCE · Frontiers in Pharmacology 2021 (PMC): Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Intranasal delivery of peptides via the olfactory and trigeminal nerve pathways has been established as a route that bypasses the blood-brain barrier entirely, with brain tissue concentrations reaching meaningful levels within 15–30 minutes in published pharmacokinetic studies. This route is particularly relevant for peptides in the 1,000–5,000 Da range, which includes BPC-157.
SOURCE · Lochhead & Thorne, Adv Drug Deliv Rev 2012; Illum, J Control Release 2003
BPC-157 has demonstrated ability to recover brain-gut axis integrity in preclinical models (PMC10224484), suggesting that both oral and nasal administration may produce secondary neurological benefits via multiple pathways — the gut-brain connection (oral) and direct CNS access (nasal).
SOURCE · PMC10224484 — Stable Gastric Pentadecapeptide BPC 157 May Recover Brain–Gut Axis
Topical BPC-157 application demonstrated accelerated wound closure in rodent alkali-burn and excisional wound models, with improved re-epithelialisation, granulation tissue formation, and tensile strength compared to untreated controls. These effects are mediated through the skin barrier only when it is disrupted — intact skin does not permit meaningful absorption at BPC-157's molecular weight.
SOURCE · PubMed 25995620; Dovepress DDDT 2022 — BPC-157 enhances alkali-burn wound healing in vivo
Protocol
How to use it.
Dosing
Sublingual (oral) spray: 500 mcg–1 mg daily, administered as 4–8 sprays per dose depending on concentration. Hold under the tongue or against the buccal mucosa for 60–90 seconds before swallowing — mucosal hold time matters for absorption. Twice daily (morning + evening, away from food) for acute GI conditions; once daily for systemic support. Nasal (intranasal) spray: Start at 200 mcg/day for 3–5 days to assess tolerance. Standard protocol: 200–500 mcg per session, 1–2× daily. Correct technique is critical — tilt head slightly forward (not backward), angle nozzle toward the ear on the same side, spray while inhaling gently (hard sniff pulls the dose past the olfactory region into the throat), hold breath 5 seconds, do not blow nose for 10 minutes. A strong metallic taste immediately after spraying indicates most of the dose hit the throat. Refrigerate at 2–8°C; use within 28 days of reconstitution. Note: RBT BPC-157 nasal spray is no longer manufactured; a TB-500 + BPC-157 combination nasal formulation may be available. Topical (wound) spray: Clean and dry the target area first. Apply a thin layer directly to the open wound or affected broken skin. Gently massage in for coverage. 1–2 applications daily. Monitor for skin irritation. Do not use on intact skin expecting systemic effects — BPC-157's molecular weight (~1,419 Da) exceeds the ~500 Da threshold for passive skin permeability.
Cycle
Sublingual: 4–8 weeks for acute GI issues (ulcers, NSAID damage, acute inflammation). 8–12 weeks for chronic conditions (leaky gut, IBD). Rest period: 4 weeks between cycles. Nasal: 4–8 weeks per cycle with 2–4 week rest between cycles. Longer cycles (8–12 weeks) for TBI recovery or chronic neurological conditions under clinical supervision. Topical: Apply for the duration of wound healing (typically 1–4 weeks depending on wound severity). Discontinue once re-epithelialisation is complete. No formal cycle length is established for cosmetic or maintenance use on unbroken skin.
Contraindications
When to skip it.
Same theoretical concerns as injectable BPC-157 apply: angiogenesis promotion (theoretical cancer risk in undiagnosed tumours). Not FDA-approved for any route or indication. Route-specific: Sublingual/oral bioavailability for systemic effects is lower than injection — not the preferred route for musculoskeletal or neurological targets. Nasal spray's brain-targeting property is a double-edged benefit — direct CNS access is powerful for brain injury but means any contaminant or impurity in the product has the same direct path. Topical spray only works on broken skin — application to intact skin produces negligible systemic absorption. Product quality varies significantly by supplier — purity and peptide stability are paramount, especially for nasal use where the olfactory nerve provides a direct brain pathway. Note: the RBT-sourced BPC-157 nasal spray has been discontinued. Verify current supplier catalog before recommending this route.
Always cleared with your concierge before protocol start.
Regulatory Context
FDA compounding status.
| FDA Status | Risk Level | Compounding | Key Date |
|---|---|---|---|
| Same as BPC-157 (PCAC Review July 2026) | 🔴 At Risk | Awaiting PCAC — regulatory status follows BPC-157 | PCAC July 23, 2026 |
Multi-route BPC-157 delivery: sublingual (gut), nasal (brain/CNS), topical (wounds). Regulatory status follows BPC-157 parent compound regardless of route. Nasal formulation availability should be verified against current RBT catalog.
Source: FDA Federal Register, PCAC agendas, industry analyses. Educational context only — not legal advice. Review after July 23-24, 2026 PCAC meeting.
Pricing
What it costs.
Indicative range for BPC Spray, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Nasal spray, ready to use
- 03Concierge supplier match included with every protocol
See BPC Spray pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $119–$179 USD